Big drugmakers must face US overcharge claims on medications for low-income patients

In a 3-0 decision, the 9th U.S. Circuit Court of Appeals in Pasadena, California said AbbVie (ABBV.N), opens new tab, AstraZeneca (AZN.L), opens new tab, Novartis (NOVN.S), opens new taband Sanofi (SASY.PA), opens new tabmust defend against claims they violated the federal False Claims Act through their involvement in the Section 340B Drug Pricing Program. Big drugmakers must face US overcharge claims on medications for low-income patients | Reuters Skip to main content Exclusive news, data and analytics fo ...